Agios Pharmaceuticals AGIO Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $113.6M+27.5% | $89.13M-3.9% | $92.71M+14.6% | $80.87M+2.4% | $78.96M+3.6% | ||
| $623.44M-18.5% | $765.3M-11.0% | $860.15M+0.2% | $858.07M+5.4% | $814.41M-0.4% | ||
| $16.13M+52.5% | $10.58M+110% | $5.03M+0.9% | $4.99M+49.1% | $3.34M-18.6% | ||
| $35.09M+6.6% | $32.92M+2.8% | $32.03M+3.8% | $30.85M+4.2% | $29.61M+7.2% | ||
| $834.84M-11.4% | $942.05M-8.8% | $1.03B+1.3% | $1.02B+5.2% | $968.62M+0.3% | ||
| $10.57M-1.9% | $10.78M+0.9% | $10.68M+0.9% | $10.58M-4.4% | $11.07M-5.2% | ||
| $1.18B-8.7% | $1.3B-6.4% | $1.39B-5.8% | $1.47B-5.4% | $1.56B-6.5% | ||
| $13.75M-25.1% | $18.36M-6.1% | $19.55M+11.5% | $17.53M+27.7% | $13.73M-17.5% | ||
| $58.85M-28.4% | $82.21M+10.0% | $74.76M+6.2% | $70.41M+34.5% | $52.37M-35.5% | ||
| $75.88M-27.1% | $104.11M+2.7% | $101.38M-0.3% | $101.68M+14.3% | $88.99M-27.2% | ||
| $76K+1.3% | $75K+1.4% | $74K0.0% | $74K0.0% | $74K+1.4% | ||
| -$660.82M-17.6% | -$561.71M-23.8% | -$453.67M-29.5% | -$350.23M-47.0% | -$238.21M-60.0% | ||
| $1.11B-7.0% | $1.19B-7.1% | $1.28B-6.2% | $1.37B-6.6% | $1.47B-4.8% | ||
| $1.18B-8.7% | $1.3B-6.4% | $1.39B-5.8% | $1.47B-5.4% | $1.56B-6.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Agios Pharmaceuticals cover its short-term obligations?
- Its current ratio is 14.19 — current assets exceed current liabilities.
- Where does Agios Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.